Background and Purpose-We aimed to determine incidences and predictors of major vascular events in intracerebral hemorrhage (ICH) survivors. Methods-We did a prospective observational cohort study in patients with spontaneous ICH from the Prognosis of Intracerebral Hemorrhage cohort in Lille, France. We studied incidences and predictors of long-term vascular events (cerebral and extracerebral, ischemic and hemorrhagic) in patients alive at 30 days with a prespecified subgroup analysis according to ICH location. We performed multivariable analyses (competing risk analyses, with death during follow-up as a competing event). Results-From the 560 patients with spontaneous ICH enrolled between November 2004 and March 2009, we included 310 patients (median age, 70 years). Eighty-two patients presented at least 1 major vascular event leading to an incidence rate of 20.0% (95% CI, 15.7-24.7) at 5 years after ICH. In the overall cohort, ischemic events were more frequent than hemorrhagic events. However, the incidence strikingly differed according to ICH location: deep ICH was associated with future ischemic events (subhazard ratio, 1.85; 95% CI, 1.01-3.40), whereas lobar ICH with hemorrhagic events (subhazard ratio, 2.38; 95% CI, 1.17-4.86). In deep ICH, the incidence of ischemic events at 5 years was 6× higher than the incidence of hemorrhagic events. Conclusions-ICH survivors are at high risk of both cerebral and extracerebral vascular events. The ischemic or hemorrhagic risk profile varies according to the index ICH location with a stronger ischemic risk in deep ICH. Secondary prevention, tailored on ICH location, should target not only cerebral recurrences but also extracerebral vascular events. (Stroke.
S pontaneous (nontraumatic) intracerebral hemorrhage (ICH) is the most dramatic type of stroke being responsible for the majority of mortality and stroke-related disability. 1 ICH survivors seem to be at high risk of major vascular events, with an ICH annual recurrence risk varying from 1.3% to 7.4%. 2 ICH location is an important factor when evaluating the risk of recurrent ICH, 3 because lobar ICH (etiologically related to cerebral amyloid angiopathy) demonstrates significantly higher recurrence rates than deep ICH (caused by deep perforating vasculopathy). 4 While patients and clinicians are mainly concerned by recurrent ICH, 5 ischemic arterial events may be at least as frequent, 2, 6 raising important therapeutic dilemmas around the net clinical benefit of antithrombotic agents in this setting. 3 However, data on the global burden of ischemic and hemorrhagic events (both cerebral and extracerebral) in ICH survivors and their predictors are still lacking.
We aimed to determine the incidence of major vascular events in ICH survivors and their associated risk factors.
Methods

Study Design and Participants
In this prospective study, we included patients from the Prognosis of Intracerebral Hemorrhage (PITCH) cohort, which is an ongoing observational study. 7 Adults over the age of 18 years consecutively admitted between November 3, 2004, and March 29, 2009 , at the Lille University Hospital with parenchymal hemorrhage on the first computed tomographic (CT) scan were included. Exclusion criteria were pure intraventricular hemorrhages; ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma, or tumor; hemorrhagic transformation within an ischemic stroke; or referral from other hospitals. The present study focused on long-term vascular recurrences during follow-up. Because of the high early mortality rate in patients with ICH, we only included patients who were alive 30 days after ICH. 8 The design of the PITCH cohort is in line with the PROGRESS (Prognosis Research Strategy) recommendations.
Procedures
We prospectively collected demographic characteristics (age and sex) and presence of vascular risk factors according to the medical history with previously published definitions. 7, 9 We recorded history of stroke
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or transient ischemic attack (TIA), ischemic heart disease, and atrial fibrillation, as defined previously. 7 At admission, we recorded the use of antihypertensive agents, antiplatelet agents, and anticoagulants. Creatinine serum levels and patient's weight were recorded to calculate the estimated glomerular filtration rate for renal function using the Modification of Diet in Renal Disease equation. This variable was dichotomized as estimated glomerular filtration rate ≥60 or <60 mL/ min per 1.73 m2 indicating impaired renal function. Preexisting level of dependency was determined with the modified Rankin Scale, a score >2 meaning dependency before ICH.
10
Baseline Radiological Assessment
Brain CT scans were performed at admission in all patients. ICH location was considered as either lobar (frontal, temporal, parietal, and occipital when the origin appeared to be in the cerebral hemispheres superficial to the deep gray matter structures), deep (when the hemorrhage originated from lenticular or caudate nucleus, thalamus, internal or external capsule, or in the posterior fossa when the hemorrhage originated from the brain stem or cerebellum), or undetermined in large ICH. The volume of the hemorrhage was calculated according to the A×B×C/2 method. 11 On CT scans, we recorded the presence of cortical atrophy on a 4-point rating scale (where a higher score denotes a severe cortical atrophy) 12 and leukoaraiosis with scores ranging from 0 to 3 (where 0 means no leukoaraiosis and 3, severe leukoaraiosis). 13 All images were rated by one board-certified neuroradiologist who assessed images blinded to clinical data.
Follow-Up Data
As part of our in-house protocol, patients were followed up at 6 months, 12 months, and annually thereafter. At each visit, we recorded the occurrence of any symptomatic stroke (ischemic or hemorrhagic) and extracerebral vascular events since last visit. We recorded the use of antihypertensive agents, antiplatelet agents, and anticoagulants. When patients were not able to come to the hospital, they were contacted by telephone. For stroke recurrences, we only considered clinical events, that is, sudden new neurological deficit, fitting with the clinical definition of ischemic stroke or ICH. For each event, all relevant neuroimaging (and where necessary the clinical notes) were reviewed to confirm the presence of either a new (distinct from index) ICH or ischemic stroke. Causes of ischemic strokes were classified according to the TOAST criteria (Trial of ORG 10172 in Acute Stroke Treatment).
14 If neuroimaging was not performed, stroke type was considered as undetermined. We did not include silent ischemic lesions, silent cerebral hemorrhages, and TIAs. We recorded the following systemic arterial vascular events: acute coronary syndrome, acute limb ischemia, coronary artery revascularization (either coronary artery bypass or percutaneous coronary intervention), severe peripheral artery disease (ie, symptomatic arterial stenosis or stenosis requiring a revascularization procedure), and severe internal carotid stenosis requiring a revascularization procedure.
Bleeding events were classified using the Bleeding Academic Research Consortium. 15 Major bleedings were defined as type ≥3 (type 3a: bleeding with hemoglobin drop of 3-5 g/dL or needing blood transfusion; type 3b: bleeding with hemoglobin drop of ≥5 g/dL or requiring surgical intervention for control or intravenous vasoactive agents; type 3c: imaging confirmed intracranial [ie, subdural, extradural, subarachnoid, pure intraventricular hemorrhages, post-traumatic ICH], intraspinal hemorrhage or intraocular bleed; type 4: coronary bypass-related bleeding; type 5: fatal bleeding). This group includes post-traumatic intracranial bleedings. For the purpose of this study, we reported nontraumatic, spontaneous ICH in a specific category.
We created a composite variable entitled major ischemic events that included both ischemic strokes and extracerebral arterial vascular events. The composite variable major hemorrhagic events included bleedings defined as Bleeding Academic Research Consortium type ≥3 and recurrent ICH. Major vascular event included any major ischemic or hemorrhagic event. All vascular events were considered as fatal when death occurred within 30 days after the acute event.
Statistical Analysis
First, we estimated cumulative incidence of major vascular events (combined and individual criteria; 30 days after ICH), considering nonvascular death as a competing risk with the approach of Prentice et al 16 ; for a given outcome, deaths that were not included in the outcome were treated as a competing event.
Bivariate comparisons of baseline characteristics between ICH location (deep and lobar index ICH) were performed using Student t test for gaussian continuous variables, Mann-Whitney U test for nongaussian continuous variables, and χ 2 test (or Fisher exact test when the expected cell frequency was <5) for categorical variables.
We investigated associations between baseline characteristics (demographic, clinical, and radiological [CT scan] data at hospital admission for ICH) and the risk of major ischemic and major hemorrhagic events in univariate and multivariable Fine-Gray models. 17 The log-linearity assumption for age (the only continuous variable) was checked after examining Martingale residual plots and using restricted cubic spline functions. 18 The ordinal variable of cortical atrophy score on CT was analyzed as 4-level categorical variables. The ordinal variable of leukoaraiosis score on CT was analyzed as 2-level categorical variable: severe leukoaraiosis (score of 3 versus 0-2). Variables associated with a P of <0.20 in bivariate analyses were implemented into a backward stepwise Fine-Gray model using a value of P<0.20 as cutoff for retention in the model. We assessed the collinearity between the candidate variables by calculating the variance inflation factors with an alert threshold value of 2.5. We assessed the proportional subhazards assumption for each potential prognostic factor by examining the Schoenfeld residuals.
Associations of anticoagulation treatment during the follow-up with major hemorrhagic events and major ischemic events were investigated using dynamic prediction in competing risks using a set of landmark type points monthly. 19 All statistical tests were done at the 2-tailed α level of 0.05. Data were analyzed using SAS, version 9.4 (SAS Institute, Inc, Cary, NC).
Ethics Protocol Approval and Patient Consents
The study protocol was regarded as observational by the Internal Review Board of the Lille University Hospital, which granted ethics approval for this study. Patients, or their relatives or primary caregiver, gave informed consent for follow-up.
The data that support the findings of this study are available from the corresponding author on reasonable request.
Results
Study Population
Of the 560 patients with spontaneous ICH enrolled in the PITCH cohort, 313 were alive at 30 days. Among them, 3 were excluded because of loss of follow-up ( Figure I in the online-only Data Supplement). The study population at 30 days consisted of 310 patients (171 [55%] were men) with a median age of 70 years (interquartile range, 57-79; Table 1 ). ICH location was deep in 195 patients and lobar in 115 patients.
During a median follow-up of 6 years (interquartile range, 1-8), 82 patients presented at least 1 major vascular event and 171 died (including 16 patients who died after the occurrence of a major vascular event), leading to a cumulative incidence rate of major vascular events of 20.0% (95% CI, 15.7-24.7) at 5 years after ICH. Treatments (antihypertensive and antithrombotic agents) used at admission for the index ICH and during follow-up are described in Table I in the online-only Data Supplement.
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Stroke Events
Sixty-one strokes occurred during follow-up in 57 patients (33 ischemic, 24 hemorrhagic, and 4 undetermined). The cumulative incidence rate of all types of stroke was 7.1% (95% CI, 4.6-10.4) at 1 year after ICH and reached 14.2% (95% CI, 10.5-18.4) at 5 years. Of the 33 patients with an ischemic stroke event, 4 events were fatal. The cumulative incidence rate of ischemic stroke was 3.2% (95% CI, 1.7-5.7) at 1 year and reached 9.0% (95% CI, 6.1-12.6) at 5 years ( Figure 1A ). Details on etiology of ischemic strokes, according to the TOAST classification, are given in Table  II in the online-only Data Supplement. Of the 24 patients with ICH recurrence, 6 events were fatal. The cumulative incidence rate of recurrent ICH was 3.9% (95% CI, 2.1-6.5) at 1 year and was 4.9% (95% CI, 2.9-7.7) at 5 years ( Figure 1A ).
Major Ischemic Events
Fifty-four patients presented at least 1 major ischemic event (including 16 coronary events). The cumulative incidence rate of all types of ischemic events (including cerebral and extracerebral) was, therefore, of 5.9% (95% CI, 3.6-8.9) at 1 year and of 15.2% (95% CI, 11.4-19.5) at 5 years ( Figure 1B ).
Major Hemorrhagic Events
Thirty-one patients presented at least 1 hemorrhagic event (including 1 gastrointestinal bleeding). The cumulative incidence rate of all types of hemorrhagic events (cerebral and extracerebral) was of 4.9% (95% CI, 2.8-7.7) at 1 year and of 6.2% (95% CI, 3.9-9.3) at 5 years ( Figure 1B ).
Impact on Outcome
Mortality related to major ischemic events (occurring within 30 days) was of 11.1% (95% CI, 4.2-22.6) and was of 19.4% (95% CI, 7.5-37.5) in major hemorrhagic events. At the end of follow-up, 27 patients of the 53 with major ischemic event as first vascular event (50.9%) and 8 patients of the 25 with major hemorrhagic event as first vascular event (32.0%) had died.
Influence of ICH Location on the Risk of Major Ischemic and Hemorrhagic Events
Cumulative incidences of major ischemic and hemorrhagic events according to ICH location are shown in Table 2 (details are given in Table III in the online-only Data Supplement). In patients with deep ICH, cumulative incidence rate of major ischemic events was of 7.3% (95% CI, 4.2-11.5), whereas cumulative incidence rate of major hemorrhagic events was of 3.1% (95% CI, 1.3-6.3) at 1 year after ICH. At 5 years, cumulative incidence rate of major ischemic events was of 18.5% (95% CI, 13.3-24.4), whereas cumulative incidence rate of major hemorrhagic events was of 3.6% (95% CI, 1.6-7.0; Figure 2A and 2B). In patients with lobar ICH, cumulative incidence rate of major ischemic events was of 3.5% (95% CI, 1.1-8.1), whereas cumulative incidence rate of major hemorrhagic events was of 7.8% (95% CI, 3.8-13.7) at 1 year after ICH. At 5 years, cumulative incidence rate of major ischemic events was of 9.8% (95% CI, 5.1-16.1), whereas cumulative incidence rate of major hemorrhagic events was of 10.5% (95% CI, 5.7-16.9; Figure 2A and 2B). Similar findings were observed when analyzing stroke subtype events only. Univariate and multivariable analyses of major ischemic and hemorrhagic events as dependent variables are presented in Tables 3 and 4 . In multivariable analyses, predictors of major ischemic events were ICH in deep location (subhazard ratio, 1.85; 95% CI, 1.01-3.40), previous history of ischemic 
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stroke and TIA, impaired renal function, diabetes mellitus, anticoagulant use at admission, and a younger age (Table 3) . Regarding predictors of major hemorrhagic events, the only predictor was the location of the ICH: patients with deep ICH had a lower risk of major hemorrhagic event during follow-up (subhazard ratio, 0.40; 95% CI, 0.20-0.82) than patients with lobar ICH (Table 4) . Anticoagulation treatment during follow-up, treated as a time-varying covariate using a landmark approach, was neither associated with major hemorrhagic events (hazard ratio, 0.81; 95% CI, 0.16-4.06; P=0.80) nor with major ischemic events (hazard ratio, 1.52; 95% CI, 0.52-4.43; P=0.44).
Discussion
In a prospective cohort of 310 consecutive ICH survivors, we found a substantial risk of major vascular events: 5 years after the ICH, 1 of 5 patients had experienced a major vascular event. Although the risk of a recurrent ICH is mostly important during the first year, clinicians should keep in mind that, in the long term, patients with ICH are at high risk of ischemic events. Our study precisely quantified for the first time longterm risks of cerebral and extracerebral major vascular events and demonstrated that these risks strikingly differed according to ICH location. Patients with deep ICH had higher incidences of major ischemic events, including ischemic strokes. Five years after a deep ICH, the rate of major ischemic events was 6× higher than the rate of major hemorrhagic events. Patients with lobar ICH had a different prognosis with a higher risk of major hemorrhagic events, mostly ICH recurrences. These results may have important clinical implications: secondary prevention strategies should be carefully tailored in patients with ICH taking into account ICH location and follow-up after ICH should be multidisciplinary. Our study has several strengths. To our knowledge, this is the first prospective study that quantified, during a median follow-up of 6 years, not only stroke recurrences but also all extracerebral vascular events, including both ischemic and hemorrhagic events. The PITCH cohort has a prospective and rigorous design. It combines the advantages of hospital-based recruitment, enabling a large sample size with detailed and standardized data collection with few missing data. Moreover, patients' characteristics at baseline are similar to those of participants in population-based recruitment, reassuring on the external validity of the PITCH cohort. 7 We carefully designed a long-term systematic and standardized assessment of all major vascular events. In ICH cohorts, death occurring during follow-up can be a major competing risk. Therefore, we chose to use competing risk models rather than survival models to address this concern.
There are some limitations to our study that warrant discussion. By excluding asymptomatic vascular events and TIAs, we might have slightly underestimated the incidence rates of ischemic events. Despite a median follow-up of 6 years, and an initial large sample size, the number of each type of events that occurred during follow-up might be regarded as low, and, therefore, we cannot exclude a risk of overfitting multivariable analyses and a loss of power to identify independent prognostic factor.
Compared with previous individual studies, we found a higher rate of cumulative incidence of all types of stroke (7.1% at 1 year and 14.2% at 5 years after ICH), including higher rates of ischemic stroke (3.2% at 1 year and 9.0% at 5 years after ICH). 5, 20 The retrospective design of prior studies, potential data miscoding bias, and shorter length of follow-up may explain the differences. Of note, in a cohort of patients, from the same region of France, with stable coronary artery disease and similar baseline characteristics, the cumulative incidence rate of ischemic stroke at 5 years was lower (2.4%; 95% CI, 1.9-2.9). 21 We were not able to discuss incidence rates of extracerebral events because no prospective data focusing on nonselected population are available to date. 22 In 2014, a meta-analysis suggested that the risk of ischemic events could be at least as high as the risk of recurrent ICH. 2 Unfortunately, the design of available studies precluded any further analyses. To our knowledge, our prospective study is the first to precisely quantify the overall risk of major ischemic events which rose from 5.9% (95% CI, 3.6-8.9) at 1 year after ICH to 15.2% (95% CI, 11.4-19.5) at 5 years after ICH. This ischemic risk largely overwhelmed the overall hemorrhagic risk that rose from 4.9% (95% CI, 2.8-7.7) at 1 year after ICH to 6.2% (95% CI, 3.9-9.3) at 5 years after ICH. Interestingly, the rise of ischemic strokes compared with ICH recurrences seems to start 1 year after ICH and persists over time ( Figure 1A and 1B) . It highlights the need of long-term follow-up and of potential benefit of interventions, such as antithrombotic use in some patients with ICH.
The weight of ischemic versus hemorrhagic events is strikingly different according to ICH location. In our population, among patients who experienced a deep ICH, the incidence of major ischemic events was 6× higher than the incidence of hemorrhagic events after 5 years of follow-up. These results highlight the fact that deep perforating vasculopathy has not only an hemorrhagic expression but also an ischemic one. Indeed, deep perforating vasculopathy is likely to be part of a dynamic multisystemic disorder affecting the small vessels beyond the brain, implicating other highly perfused organs. 23 Besides ICH location, previous history of ischemic stroke or TIA, diabetes mellitus, and impaired renal function were also predictors of major ischemic events. The long-term impact of these comorbidities probably explains why patients with major ischemic events have higher mortality rate at the end of follow-up (50.9%) compared with patients with major hemorrhagic events (30.2%).
In line with international guidelines, 24,25 92% of our cohort is treated with antihypertensive drugs 1 year after ICH. As part of our in-house protocol, patients with ICH benefit from a long-term follow-up by stroke specialists. This may explain why such a proportion of patients remained treated with antihypertensive drugs even 5 years after ICH and why the proportion of patients receiving anticoagulation during follow-up (13%) was similar to the proportion at admission (11.6%). This type of management may have had an impact on our reported incidence rates and underlines the limitation of our single-center setting. 26 However, despite specialized long-term follow-up, major vascular event rates remained high. This illustrated the big challenge of tailoring secondary prevention in such high-risk patients in a context of scarce evidence-based guidelines. 24, 25 Awaiting the results of ongoing randomized controlled trials, our data on the long-term risk of major ischemic events, in particular after deep ICH, will contribute to tailor therapeutic decisions regarding restarting or not antithrombotic drugs. At the individual level, because the risks go beyond the brain, we should promote multidisciplinary vascular follow-up.
